Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 25-32

  Patel, Dipa ^a   Bassi, Rajiv ^a   Hooper, Andrea ^a   Prewett, Marie ^a   Hicklin, Daniel J ^a   Kang, Xiaoqiang ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; Dimer; Epidermal growth factor receptor; ErbB family; Her2

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HETERODIMER; HOMODIMER; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STAT3 PROTEIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DIMERIZATION; DOWNSTREAM PROCESSING; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; FLOW CYTOMETRY; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 60749095127     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000125     Document Type: Article

References (39)

1. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
2. Jardines L, Weiss M, Fowble B and Greene M: neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 61: 268-282, 1993.
3. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20 (Suppl 18): 1-13, 2002.
4. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J and Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51: 1063-1070, 1987.
5. Valverius EM, Bates SE, Stampfer MR, Clark R, McCormick F, Salomon DS, Lippman ME and Dickson RB: Transforming growth factor alpha production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocrinol 3: 203-214, 1989.
6. Ekstrand AJ, Sugawa N, James CD and Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89: 4309-4313, 1992.
7. Noguchi M, Koyasaki N, Ohta N, Kitagawa H, Earashi M, Thomas M, Miyazaki I and Mizukami Y: Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B2 expression in patients with breast cancer. Arch Surg 128: 242-246, 1993.
8. Midulla C, Giovagnoli MR, Valli C and Vecchione A: Correlation between ploidy status, ERB-B2 and P53 immunohistochemical expression in primary breast carcinoma. Anal Quant Cytol Histol 17: 157-162, 1995.
9. Eissa S, Khalifa A, El-Gharib A, Salah N and Mohamed MK: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short term prognosis in breast cancer. Anticancer Res 17: 3091-3098, 1997.
10. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C and Osborne MP: HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12: 419-426, 1992.
11. Klapper LN, Kircschbaum MH, Sela M and Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 1: 25-79, 2000.
12. Simpson BJ, Phillips HA, Lessels AM, Langdon SP and Miller WR: c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 64: 202-206, 1995.
13. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M and Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995-5000, 1999.
14. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997.
15. Burden S and Yarden Y: Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis. Neuron 18: 847-855, 1997.
16. Stern DF and Kamps MP: EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J 7: 995-1001, 1988.
17. Lewis TS, Shapiro PS and Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139, 1998.
18. Liu W, Li J and Roth RA: Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun 261: 897-903, 1999.
19. Muthuswamy SK, Gilman M and Brugge JS: Controlled dimerization of erbB receptors provides evidence for differential signalling by homo- and heterodimers. Mol Cell Biol 19: 6845-6857, 1999.
20. Burgering BM and Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995.
21. Chan TO, Rittenhouse SE and Tsichlis PN: AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Ann Rev Biochem 68: 965-1014, 1999.
22. Goldstein NI, Prewett M, Zuklys K, Rockwell P and Mendelsohn J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 11: 1311-1318, 1995.
23. De Bono JS and Rowinsky EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. Br Med Bull 64: 227-254, 2002.
24. Giaccone G: Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23: 3235-3242, 2005.
25. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003, 2002.
26. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
27. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P and Ferguson KM: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311, 2005.
28. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999.
29. Baselga J and Albanell J: Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 (Suppl 1): 35-41, 2001.
30. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
31. Gamett D, Pearson G, Cerione R and Friedberg I: Secondary dimerization between members of the epidermal growth factor receptor family. J Biol Chem 272: 12052-12056, 1997.
32. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287, 1996.
33. Riese DJ, van Raaij TM, Plowman GD, Andrews GC and Stern DF: The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770-5776, 1995.
34. + MMTV/TGF-α bigenic mice. Proc Natl Acad Sci USA 97: 9609-9614, 2000.
35. Ye D, Mendelsohn J and Fan Z: Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18: 731-738, 1999.
36. Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu H-J, Walker F, Frenkel MJ, Hoyne PA, et al: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773, 2002.
37. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M and Shirouzu M: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787, 2002.
38. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW and Yokoyama S: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-552, 2002.
39. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000.